Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

differentiated thyroid cancer

  • You have access
    Management of Differentiated Thyroid Cancer: The Standard of Care
    Anca M. Avram, Katherine Zukotynski, Helen Ruth Nadel and Luca Giovanella
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 189-195; DOI: https://doi.org/10.2967/jnumed.121.262402
  • You have access
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study
    Lin Cheng, Ri Sa, Qiong Luo, Hao Fu, Yuchen Jin, Linglin Tang, Yi Yang, Chunjing Yu and Libo Chen
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 62-68; DOI: https://doi.org/10.2967/jnumed.120.243642
  • You have access
    Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
    Di Wu, Cristiane J. Gomes Lima, Gary Bloom, Kenneth D. Burman, Leonard Wartofsky and Douglas Van Nostrand
    Journal of Nuclear Medicine March 1, 2020, 61 (3) 397-404; DOI: https://doi.org/10.2967/jnumed.119.230730
  • You have access
    Detection at Public Facilities of 131I in Patients Treated for Differentiated Thyroid Cancer: Frequency, Sites, Management by Security Agents, and Physician Documentation Recommended for Patients
    Athanasios Bikas, Di Wu, Evelyn Bethancourt, Michael Orquiza, Gary Bloom, Kenneth D. Burman, Leonard Wartofsky and Douglas Van Nostrand
    Journal of Nuclear Medicine May 1, 2019, 60 (5) 638-643; DOI: https://doi.org/10.2967/jnumed.118.213256
  • You have access
    Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT–Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
    Donika Plyku, Robert F. Hobbs, Kevin Huang, Frank Atkins, Carlos Garcia, George Sgouros and Douglas Van Nostrand
    Journal of Nuclear Medicine July 1, 2017, 58 (7) 1146-1154; DOI: https://doi.org/10.2967/jnumed.116.179366
  • You have access
    Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study
    Esther N. Klein Hesselink, Adrienne H. Brouwers, Johan R. de Jong, Anouk N.A. van der Horst-Schrivers, Rob P. Coppes, Joop D. Lefrandt, Piet L. Jager, Arjan Vissink and Thera P. Links
    Journal of Nuclear Medicine November 1, 2016, 57 (11) 1685-1691; DOI: https://doi.org/10.2967/jnumed.115.169888
  • You have access
    124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET)
    Jakob W. Kist, Bart de Keizer, Manfred van der Vlies, Adrienne H. Brouwers, Dyde A. Huysmans, Friso M. van der Zant, Rick Hermsen, Marcel P.M. Stokkel, Otto S. Hoekstra and Wouter V. Vogel; for the THYROPET Study Group
    Journal of Nuclear Medicine May 1, 2016, 57 (5) 701-707; DOI: https://doi.org/10.2967/jnumed.115.168138
  • You have access
    DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy
    Uta Eberlein, Harry Scherthan, Christina Bluemel, Michel Peper, Constantin Lapa, Andreas Konrad Buck, Matthias Port and Michael Lassmann
    Journal of Nuclear Medicine February 1, 2016, 57 (2) 173-179; DOI: https://doi.org/10.2967/jnumed.115.164814
  • You have access
    Differentiated Thyroid Cancer Patients More Than 60 Years Old Paradoxically Show an Increased Life Expectancy
    Tobias Markus Maier, Otmar Schober, Joachim Gerß, Dennis Görlich, Christian Wenning, Michael Schaefers, Burkhard Riemann and Alexis Vrachimis
    Journal of Nuclear Medicine February 1, 2015, 56 (2) 190-195; DOI: https://doi.org/10.2967/jnumed.114.150284
  • You have access
    Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients
    Jeong Won Lee, Sang Mi Lee, Dae Ho Lee and Yeo Joo Kim
    Journal of Nuclear Medicine August 1, 2013, 54 (8) 1230-1236; DOI: https://doi.org/10.2967/jnumed.112.117119

Pages

  • Next
  • 1
  • 2
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire